arket access, Values arbitration and Pricing of innoVatiVe Medicines 7th descartes-berkeley symposium on Health economics – Paris, May 24th, 2012

Abstract

Across global borders and throughout the various sectors of health care, the search for viable methods to pay for value has intensified. Driven by soaring costs and constrained budgets, public and private payers are seeking innovative ways to incentivize providers and product manufacturers to focus on effective outcomes for patients. This 7th Descartes-Berkeley symposium discussed methods of conditional pricing and other insurer strategies for the management of expensive innovative drugs. Risks-sharing agreements between payers and producers facilitate market access in a context of financial crisis, loss of reciprocal confidence, and growing aversion for therapeutic and economical uncertainty. The open discussion between academics, researchers, producers and insurers has shown that performance-based agreements could be used within the French context of market access and pricing. It would be a means to restore confidence and visibility for the future. In this context, facial prices are for our French School a basic issue for stabilizing international trade. (these abstracts of the symposium will be developed as papers in a book to be published soon, with papers from complementary contributors).